Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 49

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 49
---
 directors deems relevant. As a result, you should expect to receive a return on your investment in
our Common Stock only if the market price of the Common Stock increases, which may never occur.

Risks Relating to this Offering

Since this is a self-underwritten offering by the Company, no independent third party such as an underwriter conducted any due diligence on the accuracy of the information in this prospectus.

In an underwritten offering, the underwriter
conducts an independent due diligence of the company. Since there is no underwriter in this Primary Offering, none of the information
contained in the registration statement of which this prospectus is a part of has been independently verified or confirmed. Moreover,
the price of the Units being offered in the Offering was arbitrarily determined by us, and said price has no relation to our business,
assets or any other indica.

As a best efforts offering, no minimum amount of securities is required to be sold, and we may not raise the amount of capital we believe is required for our business plans.

We are attempting to raise an aggregate of $5,000,000
without the assistance of any underwriter, placement agent or any other third party. There is no required minimum number of units that
must be sold as a condition to completion of this offering. Because there is no minimum offering amount required as a condition to the
closing of this offering, the actual offering amount is not presently determinable and may be substantially less than the maximum amount
we are attempting to raise. We may sell fewer than all of the units offered hereby, which may significantly reduce the amount of proceeds
received by us, and investors in this offering will not receive a refund in the event that we do not sell any minimum amount of units.
Thus, we may not raise the amount of capital we believe is required for our operations in the short-term and may need to raise additional
funds, which may not be available or available on terms acceptable to us.

Because the Company is offering to sell Units Comprised of two shares of our Common Stock and one warrant for an additional share of Common Stock at an expected public offering price $3.20 per Unit and, afterour Common Stock is quoted on the OTCQX or the OTCQB marketplace of OTC Market or our Common Stock are listed on a national securities exchange, the Selling Shareholders will be offering to sell shares at the then-prevailing market price, purchasers of shares from the Selling Shareholders could pay more or less per share than investors in